Related Experiment Videos
Oral bropirimine immunotherapy of rodent prostate cancer
1Division of Urology, University of Texas Health Science Center, San Antonio 78284-7845, USA.
Objective:
Bropirimine is an oral immunostimulant found to have efficacy in human transitional cell carcinoma in situ following the initial discovery of its antitumor activity against the murine bladder cancer MBT-2. To determine if bropirimine might have activity in prostate cancer, it was tested against two rodent prostate cancer cell lines in vivo.
Methods:
Tumors resulted from subcutaneous injection of PAIII and Dunning MAT-LyLu rodent prostate cancer cells. Bropirimine was given at 250 mg/kg orally on different schedules, and tumor volume and survival were recorded.
Result:
In the PAIII model, bropirimine prevented growth when given the day of tumor injection, and 95% of advanced tumors regressed completely when start of therapy was delayed. Bropirimine also caused growth inhibition and prolongation of survival in the MAT-LyLu model.
Conclusions:
Bropirimine immunotherapy is very effective in vivo against the PAIII cell line, and it has significant growth inhibition against the Dunning MAT-LyLu cell line.
Insights
Bropirimine, an oral immunostimulant, demonstrated significant effectiveness against rodent prostate cancer models. It prevented tumor growth and caused regression in one model, while inhibiting growth and extending survival in another.
Area of Science:
- Oncology
- Immunotherapy
Background:
- Bropirimine is an oral immunostimulant with known antitumor activity.
- Previous studies showed efficacy in human transitional cell carcinoma and murine bladder cancer.
Purpose of the Study:
- To evaluate the efficacy of bropirimine in rodent prostate cancer models.
- To determine if bropirimine has potential as a prostate cancer treatment.
Main Methods:
- Two rodent prostate cancer cell lines (PAIII and Dunning MAT-LyLu) were used.
- Bropirimine was administered orally at 250 mg/kg.
- Tumor volume and animal survival were monitored.
Main Results:
- Bropirimine prevented tumor growth in the PAIII model when administered at tumor injection.
- Complete regression of advanced PAIII tumors was observed in 95% of cases with delayed therapy.
- Bropirimine inhibited tumor growth and prolonged survival in the MAT-LyLu model.
Conclusions:
- Bropirimine immunotherapy is highly effective against the PAIII prostate cancer cell line in vivo.
- Bropirimine exhibits significant growth inhibition against the Dunning MAT-LyLu prostate cancer cell line.